Insider Buying: AnaptysBio, Inc. (NASDAQ:ANAB) Director Purchases $86,065.70 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc purchased 6,646 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was acquired at an average price of $12.95 per share, with a total value of $86,065.70. Following the completion of the purchase, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, December 30th, Ecor1 Capital, Llc acquired 65,184 shares of AnaptysBio stock. The stock was acquired at an average price of $12.92 per share, for a total transaction of $842,177.28.

AnaptysBio Trading Up 9.3 %

Shares of ANAB stock opened at $14.60 on Friday. AnaptysBio, Inc. has a 12-month low of $12.51 and a 12-month high of $41.31. The stock has a market capitalization of $444.26 million, a P/E ratio of -2.40 and a beta of -0.02. The firm’s 50 day moving average is $19.75 and its 200 day moving average is $28.43.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, equities analysts predict that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. reduced their price target on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Truist Financial dropped their price target on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Wedbush restated an “outperform” rating and set a $40.00 price objective (down from $42.00) on shares of AnaptysBio in a research note on Wednesday, December 11th. Finally, Guggenheim dropped their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and an average target price of $41.45.

Institutional Investors Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its holdings in shares of AnaptysBio by 191.4% in the third quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company’s stock worth $1,130,000 after buying an additional 22,164 shares during the last quarter. Barclays PLC boosted its stake in shares of AnaptysBio by 117.4% during the 3rd quarter. Barclays PLC now owns 44,300 shares of the biotechnology company’s stock worth $1,486,000 after acquiring an additional 23,926 shares during the last quarter. Geode Capital Management LLC grew its position in shares of AnaptysBio by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company’s stock valued at $15,594,000 after acquiring an additional 13,336 shares during the period. Frazier Life Sciences Management L.P. grew its position in shares of AnaptysBio by 2.0% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after acquiring an additional 43,598 shares during the period. Finally, XTX Topco Ltd raised its holdings in AnaptysBio by 49.1% in the 3rd quarter. XTX Topco Ltd now owns 20,286 shares of the biotechnology company’s stock worth $680,000 after purchasing an additional 6,683 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.